title: [Compound erythromycin sustained release preparation and its in vitro release].
abstract: Using the weight-average molecular weight 50 000 polylactic acid (PLA) as a carrier, and a certain proportion of erythromycin (EM) and prednisone acetate (PNA) to mixed prepare the compound erythromycin sustained release preparation (sustained-release tablets). Using ultraviolet spectrophotometry and high performance liquid chromatography (HPLC) to detect separately the release amount of EM and PNA in vitro medium. The sustained-release tablets release for about 21 days, the average content of EM is 99.7 mg/table, RSD = 0.82%; and the average content of PNA is 10.03 mg/table, RSD = 0.93%. Within 21 days, the cumulative releases of EM and PNA are 86.1% and 78.3%, respectively. The drug release is steady and slow after 5 days, the burst release phenomenon in early stage is more significant. The results showed that the sustained-release tablet preparation method is feasible, the release performance is good and the clinical efficacy is significant.
authors.affiliation: Department of Pharmacy of the Qilu Hospital of Shandong University, Jinan 250012, China.
authors.forename: Hai-xia
authors.initials: HX
authors.lastname: Chen
authors.forename: Zhi-peng
authors.initials: ZP
authors.lastname: Chen
authors.forename: Qi-rong
authors.initials: QR
authors.lastname: Wang
authors.forename: Ze-kun
authors.initials: ZK
authors.lastname: Liu
authors.forename: Quan-long
authors.initials: QL
authors.lastname: Ma
mesh_terms: D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D004337:Drug Carriers; D004338:Drug Combinations; D004917:Erythromycin / Q000008:administration & dosage* / Q000737:chemistry* / Q000627:therapeutic use; D006801:Humans; D019344:Lactic Acid / Q000008:administration & dosage; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage* / Q000737:chemistry* / Q000627:therapeutic use; D012852:Sinusitis / Q000188:drug therapy; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004338:Drug Combinations; D011091:Polyesters; D011108:Polymers; D013607:Tablets; D019344:Lactic Acid; C033616:poly(lactide); D004917:Erythromycin; D011241:Prednisone